Akcea and Ionis’ Tegsedi (inotersen) received marketing authorization approval from the European Commission for treating stage 1 or stage 2 polyneuropathy in adults with hATTR.

Paris-based Sanofi has acquired Waltham, Mass.-based Bioverativ for about $11.6 billion.